论文部分内容阅读
[目的]探讨趋化因子CXCL5及其受体CXCR2与肝细胞癌(HCC)的临床病理特征和术后复发的关系。[方法]根据随访结果,分为早期复发组、非早期复发组和无复发组。运用荧光定量PCR检测3组肝癌患者组织中CXCL5和CXCR2的相对表达量。[结果]CXCL5在早期复发组的相对表达量高于无复发组(P=0.011);与临床分期和HBsAg状态有关(P<0.05)。CXCR2在早期复发组的相对表达量高于无复发组(P<0.001),同时高于非早期复发组(P=0.005);与临床分期、肿瘤直径和HBsAg状态有关(P<0.05)。CXCL5-CXCR2共同高表达患者的5年累积生存率明显低于其他患者(P=0.005)。[结论]CXCL5和CXCR2在肝癌中高表达,并与临床病理特征和术后复发有关。CXCL5和CXCR2有望成为肝癌术后预后判断的指标。
[Objective] To investigate the relationship between chemokine CXCL5 and its receptor CXCR2 and the clinicopathological features and recurrence of hepatocellular carcinoma (HCC). [Methods] According to the follow-up results, divided into early recurrence group, non-early recurrence group and no recurrence group. Fluorescent quantitative PCR was used to detect the relative expression of CXCL5 and CXCR2 in three groups of liver cancer patients. [Results] The relative expression level of CXCL5 in early recurrence group was higher than that in non recurrence group (P = 0.011), and was related to clinical stage and HBsAg status (P <0.05). The relative expression of CXCR2 in early recurrence group was higher than that in non-recurrence group (P <0.001), and higher than that in non-early recurrence group (P = 0.005). It was correlated with clinical stage, tumor diameter and HBsAg status (P <0.05). The 5-year cumulative survival of patients with CXCL5-CXCR2 overexpression was significantly lower than that of other patients (P = 0.005). [Conclusion] CXCL5 and CXCR2 are highly expressed in hepatocellular carcinoma, and are associated with clinicopathological features and postoperative recurrence. CXCL5 and CXCR2 are expected to be indicators of postoperative prognosis of liver cancer.